Health Economics›Prostate cancer›Metastatic disease second-line hormonal therapy

Metastatic disease second-line hormonal therapy

Prostate cancer · 11 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 3 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Abiraterone and Olaparib Variant #01	—	R 52 158	21d	—	~42.1 mo	~10	~R 521 577 PFS proxy · indirect	1
Abiraterone and Apalutamide Variant #01	—	R 44 092	28d	—	—	~2	~R 88 184 indirect	—
Apalutamide monotherapy Variant #01	—	R 33 772	28d	—	—	~2	~R 67 545 indirect	—
Enzalutamide monotherapy Variant #01	—	R 14 528	28d	~4.2 mo	~17.5 mo	~2	~R 29 057 PFS proxy · indirect	13
Abiraterone monotherapy Variant #01	—	R 10 320	28d	~4.9 mo	~15.4 mo	~2	~R 20 639 PFS proxy · indirect	9
Ketoconazole, Hydrocortisone, Dutasteride Variant #01	—	R 5 357	28d	—	—	~2	~R 10 714 indirect	—
Ketoconazole and Hydrocortisone Variant #01	—	R 5 068	28d	—	—	~2	~R 10 135 indirect	—
Hydrocortisone monotherapy Variant #01	—	R 1 701	28d	—	~12.6 mo	~2	~R 3 403 PFS proxy · indirect	—
Prednisone monotherapy Variant #11 Partial	—	R 138	7d	~2.2 mo	~14.1 mo	~1	~R 138 PFS proxy · indirect	8
Antiandrogen withdrawal Partial	—	—	—	—	—	—	—	—
BAT Variant #01 Partial	—	—	28d	~5.7 mo	—	~2	—	—

11 of 11 regimens shown